Share on StockTwits

Immunogen (NASDAQ:IMGN) CEO Daniel M. Junius unloaded 15,000 shares of Immunogen stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $16.26, for a total value of $243,900.00. Following the sale, the chief executive officer now directly owns 80,636 shares in the company, valued at approximately $1,311,141. The transaction was disclosed in a filing with the SEC, which is available at this link.

A number of research firms have recently commented on IMGN. Analysts at Guggenheim raised their price target on shares of Immunogen from $14.00 to $15.00 in a research note on Friday, January 31st. Separately, analysts at Zacks downgraded shares of Immunogen from an “outperform” rating to a “neutral” rating in a research note on Monday, January 27th. They now have a $18.20 price target on the stock. Finally, analysts at Zacks upgraded shares of Immunogen from a “neutral” rating to an “outperform” rating in a research note on Friday, December 27th. They now have a $16.60 price target on the stock. Two research analysts have rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $17.79.

Shares of Immunogen (NASDAQ:IMGN) traded up 3.35% during mid-day trading on Thursday, hitting $16.36. The stock had a trading volume of 272,513 shares. Immunogen has a 52-week low of $12.55 and a 52-week high of $20.25. The stock’s 50-day moving average is $15.39 and its 200-day moving average is $15.81. The company’s market cap is $1.402 billion.

Immunogen (NASDAQ:IMGN) last posted its quarterly earnings results on Friday, January 31st. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.11. The company had revenue of $30.10 million for the quarter, compared to the consensus estimate of $18.16 million. During the same quarter in the previous year, the company posted ($0.29) earnings per share. The company’s revenue for the quarter was up 1057.7% on a year-over-year basis. On average, analysts predict that Immunogen will post $-0.67 earnings per share for the current fiscal year.

ImmunoGen, Inc (NASDAQ:IMGN) develops targeted, antibody-based therapeutics for the treatment of cancer.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.